Acurx Pharmaceuticals, Inc.ACXPNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank60
3Y CAGR-82.3%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-82.3%/yr
Annual compound
Percentile
P60
Within normal range
vs 3Y Ago
0x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2024 | 1.93% |
| 2023 | 16.29% |
| 2022 | -31.95% |
| 2021 | 349.89% |
| 2020 | -1.00% |
| 2019 | 0.00% |